Cyclosporine's toxic side effects are well documented namely hypertension, nerotoxicity, nephrotoxicity, etc. ISA247's selling point is that it will hopefully be able to maintain cyclosporines efficacy without the side effects.
In the upcoming European psoriasis trial along with the 247 and placebo arms will also be a cyclosporine arm. From my understanding cyclosporine is used much more frequently in Europe than N.A. for psoriasis and the head to head comparison of 247 against cyclosporine will highlight the side effect disparities which should help 247 be better accepted in Europe if approved.
fid
Market Data 
Markets 
AI
